An investor in NASDAQ:NTRP shares filed a lawsuit over alleged violations of Federal Securities Laws by Neurotrope Inc.
Investors who purchased shares of Neurotrope Inc (NASDAQ:NTRP) should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The plaintiff claims that between January 7, 2016, and April 28, 2017 Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1.
On May 1, 2017, Neurotrope Inc announced “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope Inc failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Shares of Neurotrope Inc (NASDAQ:NTRP) declined to $6.42 per share on May 15, 2017.
Those who purchased NASDAQ:NTRP shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego